VitaNova Life Sciences Corp
No enriched coverage for $VNOV in the last 7 days.
No SEC Form 4 filings for $VNOV in the last 30 days.
See all $VNOV insider activity →VitaNova (VNOV) reported a 210% revenue increase to $321,576 for the quarter ended July 31, 2026, driven by new food products. However, gross margin dropped to 9% from 66%, and net loss widened to $123,101. The company cited internal control weaknesses but stated it has sufficient liquidity for the next 12 months.
Earnings beat on top line but severe margin compression and widening loss suggest near‑term price pressure.
AlphAI scores every news story that mentions VNOV with an AI model for sentiment and relevance, and aggregates insider trades from VitaNova Life Sciences Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
VitaNova (VNOV) reported a 210% revenue increase to $321,576 for the quarter ended July 31, 2026, driven by new food products. However, gross margin dropped to 9% from 66%, and net loss widened to $123,101. The company cited internal control weaknesses but stated it has sufficient liquidity for the next 12 months.
2 min read